Group 1 - On September 15, Baicheng Pharmaceutical experienced a decline of 0.48% with a trading volume of 198 million yuan, and the financing net buy was -2.73 million yuan [1] - As of September 15, the total margin balance for Baicheng Pharmaceutical was 251 million yuan, accounting for 3.71% of its market capitalization, indicating a high level compared to the past year [1] - The company’s main business revenue composition includes: 32.19% from technology transfer, 24.50% from clinical services, 23.56% from preclinical research, 10.28% from commercial production, and 3.50% from CDMO services [1] Group 2 - As of June 30, the number of shareholders for Baicheng Pharmaceutical was 11,900, a decrease of 26.69%, while the average circulating shares per person increased by 62.65% to 6,976 shares [2] - For the first half of 2025, Baicheng Pharmaceutical reported a revenue of 332 million yuan, a year-on-year decrease of 36.70%, and a net profit attributable to shareholders of 3.10 million yuan, down 97.69% year-on-year [2] Group 3 - Baicheng Pharmaceutical has distributed a total of 184 million yuan in dividends since its A-share listing, with 119 million yuan distributed over the past three years [3] - As of June 30, 2025, the eighth largest circulating shareholder was Rongtong Health Industry Flexible Allocation Mixed A/B, holding 1.20 million shares, a decrease of 100,000 shares from the previous period [3]
百诚医药9月15日获融资买入2734.19万元，融资余额2.51亿元